Amid a record bad year, Bellicum keeps taking its lumps as FDA slams trial hold on CAR-T hopeful

It’s been no less than a disastrous year for Houston biotech Bellicum Pharmaceuticals after taking a scalpel to its pipeline and dumping a vast majority of its staff. Now, in an already-doomed trial of one of Bellicum’s next-gen oncology hopefuls, the FDA is doling out even more lumps.